DarioHealth Corp.

NASDAQ:DRIO

Medical - Diagnostics & Research

Healthcare
$5.13 -1.68%

-$0.12 today

Market cap
$50.27M
Beta
1.08
P/E (TTM)
5.5
EPS (TTM)
$1.26
52W Low $5.94High $17.74

Volume 0.01M

Average 0.01M

DRIO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

DarioHealth Corp.NASDAQ: DRIO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $2.38M fell 16.9% year over year, behind the -2.6% change in trailing-twelve-month cost of revenue. Sequentially, it fell 16.6% from the prior quarter. Over 3 fiscal years it compounded at -18.6% a year.

Context

  • Cost of revenue amounted to 43.4% of revenue in FY2025, down 7.6 pp from a year earlier.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -16.9% toward the trailing-twelve-month pace of -2.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.38M-16.6% QoQ
Last fiscal yearDec 2025
$9.69M-29.6% YoY
LTMMar 2026
$9.21M-2.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.9%——
1 year-29.6%——
3-year CAGR-18.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
9.69M USD
Year-over-year change
-29.6%
4-year CAGR
-6.1%

Cost of Revenue vs competitors

How DRIO compares with its peers on the latest reported figures

  • DRIO's LTM Mar 2026 cost of revenue of $9.21M is the 9th highest of the 11 companies compared; the peer median is $148.51M.
  • Its year-over-year change of -2.6% is the 6th highest of 10, against a peer median of -0.1%.
  • Cost of revenue amounts to 43.5% of revenue for DRIO, versus a peer median of 56.4%.
DRIO Competitors Peer median
Cost of Revenue for DRIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INNVInnovAge Holding Corp.LTM Mar 2026$749.65M +9.8%-21.8%79.3%
AVNSAvanos Medical, Inc.LTM Mar 2026$368.3M +18.2%+6.7%51.4%
OFIXOrthofix Medical Inc.LTM Mar 2026$255.74M -3.2%+29.9%31.0%
MYGNMyriad Genetics, Inc.LTM Mar 2026$249M -0.1%+7.1%30.0%
FLGTFulgent Genetics, Inc.LTM Mar 2026$196.33M +9.7%-8.7%61.3%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$100.69M -21.2%+11.3%62.9%
RGNXREGENXBIO Inc.LTM Mar 2026$87.94M +139.2%-28.1%100.1%
ABSIAbsci CorporationLTM Mar 2026$26.01M -49.9%-41.6%1416.9%
DRIODarioHealth Corp.LTM Mar 2026$9.21M -2.6%-18.6%43.5%
VSTMVerastem, Inc.LTM Mar 2026$8.06M ——16.3%
NNNNAnbio Biotechnology Class A Ordinary SharesFY2025$1.25M -45.8%-51.6%12.8%
Peer median (excluding DRIO) $148.51M-0.1%-8.7%56.4%

Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.51M27.66M20.35M27.04M22.36M
Cost of Revenue12.44M18M14.37M13.77M9.69M
Gross Profit8.07M9.66M5.98M13.27M12.67M
Gross Margin39.3%34.9%29.4%49.1%56.6%
Research & Development17.22M19.65M20.25M24.18M13.79M
Selling, General & Admin62.36M46.82M41.8M46.83M35.53M
Operating Expenses84.56M66.47M62.17M71.01M49.32M
Depreciation & Amortization4.46M4.72M4.99M7.43M3.56M
EBITDA(70.02M)(55.6M)(54.38M)(37.08M)(34.69M)
EBITDA Margin-341.3%-201.0%-267.2%-137.1%-155.2%
Operating Income(76.49M)(56.81M)(56.19M)(57.74M)(36.66M)
Operating Margin-372.9%-205.4%-276.1%-213.6%-163.9%
Interest Income44K506K1.87M1.12M943K
Interest Expense84K2.68M645K96K3.36M
Other Income / Expenses(235K)(5.38M)(3.17M)13.15M(4.95M)
Income Before Tax(76.73M)(62.19M)(59.36M)(44.6M)(41.61M)
Pre-Tax Margin-374.1%-224.9%-291.7%-164.9%-186.1%
Income Tax Expense32K4K64K(1.85M)105K
Net Income(76.76M)(62.19M)(59.43M)(42.75M)(41.71M)
Net Margin-374.2%-224.9%-292.0%-158.1%-186.6%
EPS (Basic)(4.63)(2.63)(1.93)(0.74)1.24
EPS (Diluted)(4.63)(2.63)(1.93)(0.74)1.24
Weighted Avg Shares16.59M23.64M28.37M40.42M49.63M
Weighted Avg Shares (Diluted)16.59M23.64M28.37M40.42M49.63M

DarioHealth Corp.

NASDAQ:DRIO

Intrinsic Alpha fair value

Locked

Current Price

$5.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.